LAMICTAL CD |
LAMOTRIGINE |
BW-430C |
LAMICTAL ODT |
LAMICTAL |
LAMICTAL XR |
LAMOTRIGINUM |
QÍN |
LAMICTAL® |
LAMOTRIGINA |
3,5-DIAMINO-6-(2,3-DICHLOROPHENYL)-1,2,4-TRIAZINE |
GIZORD |
QIN |
drugbank:00555 |
pubchem.compound:3878 |
chembl:CHEMBL741 |
rxcui:28439 |
chemidplus:84057-84-1 |
FDA Approval | approved |
Drug Class | Small Molecule |
Drug Indications | anticonvulsant |
Drug Categories | agents causing hyperkalemia |
Drug Categories | agents producing tachycardia |
Drug Categories | anti-epileptic agent |
Drug Categories | antiarrhythmic agents |
Drug Categories | anticholinergic agents |
Drug Categories | bradycardia-causing agents |
Drug Categories | calcium-regulating hormones and agents |
Drug Categories | cytochrome p-450 cyp3a substrates |
Drug Categories | cytochrome p-450 cyp3a4 substrates |
Drug Categories | cytochrome p-450 substrates |
Drug Categories | decreased central nervous system disorganized electrical activity |
Drug Categories | drugs causing inadvertant photosensitivity |
Drug Categories | drugs that are mainly renally excreted |
Drug Categories | miscellaneous anticonvulsants |
Drug Categories | mood stabilizer |
Drug Categories | muscarinic antagonists |
Drug Categories | oct1 substrates |
Drug Categories | oct2 inhibitors |
Drug Categories | p-glycoprotein inhibitors |
Drug Categories | p-glycoprotein substrates |
Drug Categories | photosensitizing agents |
Drug Categories | potential qtc-prolonging agents |
Drug Categories | psychotropic drugs |
Drug Categories | qtc prolonging agents |
Drug Categories | tranquilizing agents |
Drug Categories | triazines |
Drug Categories | ugt1a1 inducers |
Drug Categories | ugt1a1 substrates |
Drug Categories | ugt1a3 substrates |
Drug Categories | ugt1a4 substrates |
blocker (inhibitory) |
inhibitor (inhibitory) |
Trial Name | Lamictal |
Novel drug target | Established target |
Mechanism of Interaction | Sodium channel alpha subunit blocker |
blocker (inhibitory) |
Mechanism of Interaction | Sodium channel alpha subunit blocker |
Direct Interaction | yes |
blocker (inhibitory) |
Mechanism of Interaction | Sodium channel alpha subunit blocker |
Direct Interaction | yes |
blocker (inhibitory) |
Mechanism of Interaction | Sodium channel alpha subunit blocker |
Direct Interaction | yes |
blocker (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Sodium channel alpha subunit blocker |
blocker (inhibitory) |
Mechanism of Interaction | Sodium channel alpha subunit blocker |
Direct Interaction | yes |
blocker (inhibitory) |
Mechanism of Interaction | Sodium channel alpha subunit blocker |
Direct Interaction | yes |
blocker (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Sodium channel alpha subunit blocker |
blocker (inhibitory) |
Mechanism of Interaction | Sodium channel alpha subunit blocker |
Direct Interaction | yes |
LAMOTRIGINE | DrugBank Drug Name |
84057-84-1 | CAS Number |
Apo-lamotrigine | Drug Brand |
Drug Type | small molecule |
Drug Groups | approved |
Drug Groups | investigational |
Drug Indications | anticonvulsant |
Drug Class | Small Molecule |
FDA Approval | approved |
C38703 | NCI drug code |
CHEMBL741 | ChEMBL Drug ID |
D03FLC | TTD Drug ID |